Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NTHI | PRESS-RELEASE | bearish | 6/10 | NeOnc reported Q1 2026 EPS of -$0.38, a 245.5% miss vs consensus of -$0.11, with zero revenue. The net loss improved YoY | May 18, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine filed an 8-K announcing management will present at A.G.P.'s Annual Virtual Healthcare Company Showcase on May 2 | May 18, 2026 |
| EVFM | 8-K | neutral | 4/10 | Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M vs net income of $1.0 | May 18, 2026 |
| NNVC | 424B5 | bearish | 6/10 | NanoViricides is conducting a registered direct offering of 1,133,334 shares of common stock at $1.50/share, pre-funded | May 18, 2026 |
| DWTX | PRESS-RELEASE | bullish | 7/10 | Dogwood Therapeutics announced the commencement of a 12-week open-label extension study for its lead candidate Halneuron | May 18, 2026 |
| SCNX | PRESS-RELEASE | bullish | 6/10 | Scienture reported Q1 2026 revenue of $56K (up 449% YoY from $10K) and EPS of -$0.08, beating consensus of -$0.23 by 65. | May 18, 2026 |
| SLXNW | 8-K | bullish | 7/10 | Silexion Therapeutics reported Q1 2026 financial results, highlighting a net loss of $2.7M (vs $1.7M in Q1 2025) and cas | May 18, 2026 |
| FBIO | PRESS-RELEASE | neutral | 2/10 | Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is | May 18, 2026 |
| SLXN | PRESS-RELEASE | bullish | 7/10 | Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancre | May 18, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced the formation of a wholly owned Nevada subsidiary, Quantum Drones Corporation, to pursue U.S. go | May 18, 2026 |
| BGM | 6-K | bearish | 7/10 | BGM Group Ltd. entered into a securities purchase agreement for a private placement of 200,000,000 Class A ordinary shar | May 18, 2026 |
| TTRX | 8-K | bullish | 5/10 | Turn Therapeutics appointed Dr. Stephen M. Hahn, former FDA Commissioner, as Executive Clinical and Regulatory Lead to o | May 18, 2026 |
| ENLV | 6-K | neutral | 4/10 | Enlivex dosed the first U.S. patient in its Phase 2b trial of Allocetra for knee osteoarthritis, following FDA IND clear | May 18, 2026 |
| TEVA | PRESS-RELEASE | neutral | 3/10 | Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) wi | May 18, 2026 |
| MEHA | 8-K | bearish | 6/10 | Functional Brands Inc. reported Q1 2026 revenue of $1.65M (+3.5% YoY) and gross margin expansion of 390 bps to 58.4%, bu | May 18, 2026 |
| STTK | CLUSTER | neutral | 3/10 | Two STTK insiders (CMO and CTO) sold a combined $212K in open-market sales on May 12, 2026, following the Q1 earnings re | May 18, 2026 |
| FOXOW | 8-K | mixed | 6/10 | FOXO Technologies exchanged all outstanding Series A Convertible Preferred Stock held by two institutional investors (Sa | May 18, 2026 |
| CRVO | PRESS-RELEASE | mixed | 6/10 | CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened to -$8.0M from -$4.9 | May 18, 2026 |
| NGEN | PRESS-RELEASE | bearish | 6/10 | NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% miss on the Street-qu | May 18, 2026 |
| DSGN | 8-K | bullish | 7/10 | Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial of DT-216P2 in Fr | May 18, 2026 |
| GOSS | DEFA14A | mixed | 7/10 | Gossamer Bio launched an exchange offer to swap up to $200M of 5.00% convertible notes due 2027 for $72M of new 7.50% se | May 18, 2026 |
| LNZAW | 8-K | bearish | 7/10 | LanzaTech Global, Inc. entered into a Securities Purchase Agreement on May 15, 2026, to sell 2,000,000 shares of common | May 18, 2026 |
| REGN | PRESS-RELEASE | neutral | 4/10 | Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates | May 18, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced participation as an exhibitor at SOF Week 2026, a premier defense convention. The event provides | May 18, 2026 |
| NRXP | PRESS-RELEASE | bullish | 6/10 | NRx Pharmaceuticals reported Q1 2026 EPS of -$0.04, beating consensus of -$0.13 by 69.2%, with net loss narrowing to $1. | May 18, 2026 |
| LNZAW | 424B5 | bearish | 7/10 | LanzaTech Global, Inc. is offering 2,000,000 shares of common stock at $10.00 per share, raising approximately $18.33 mi | May 18, 2026 |
| DSGN | PRESS-RELEASE | bullish | 8/10 | Design Therapeutics announced positive Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich ataxia, showing dose-depende | May 18, 2026 |
| CGEN | 6-K | neutral | 4/10 | Compugen reported Q1 2026 results with revenue of $2.2M (vs $2.3M in Q1 2025) and net loss of $7.7M ($0.08/share) vs $7. | May 18, 2026 |
| CNTX | PRESS-RELEASE, 8-K | bullish | 7/10 | Context Therapeutics amended its license agreement with BioAtla for CT-202, buying out all future milestone and royalty | May 18, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May | May 18, 2026 |